(Q40706273)

22 September 2017

title

Current histological classification of NAFLD: strength and limitations (English)

1 reference

22 September 2017

Pierre Bedossa

1

0 references

publication date

18 July 2013

1 reference

22 September 2017

published in

Hepatology international

1 reference

22 September 2017

volume

7 Suppl 2

1 reference

22 September 2017

page(s)

765-770

1 reference

https://scigraph.springernature.com/pub.10.1007/s12072-013-9446-z

22 September 2017

exact match

0 references

cites work

The epidemiology of nonalcoholic fatty liver disease: a global perspective

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

Epidemiology and natural history of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

Sampling variability of liver fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

Sources of variability in histological scoring of chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

New imaging techniques for non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

Nonalcoholic fatty liver disease: pathology and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

Histopathology of pediatric nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

Endpoints and clinical trial design for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

Triglyceride accumulation protects against fatty acid-induced lipotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-013-9446-Z

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

21 January 2018

1 reference

12 December 2020

Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial

1 reference

12 December 2020

The incapacity of the surgeon to identify NASH in bariatric surgery makes biopsy mandatory

1 reference

12 December 2020

Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis

1 reference

12 December 2020

Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology

1 reference

12 December 2020

Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease

1 reference

12 December 2020

Does liver appearance predict histopathologic findings: prospective analysis of routine liver biopsies during bariatric surgery

1 reference

12 December 2020

Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality

1 reference

12 December 2020

Misuse of scoring systems

1 reference

12 December 2020

10.1007/S12072-013-9446-Z

Identifiers

DOI

1 reference

22 September 2017

1 reference